Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis

Lucy C. Okell; Matthew Cairns; Jamie T. Griffin; Neil M. Ferguson; Joel Tarning; George Jagoe; Pierre Hugo; Mark Baker; Umberto D’Alessandro; Teun Bousema; David Ubben; Azra C. Ghani

doi:10.1038/ncomms6606

Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis

Nature Communications ◽

10.1038/ncomms6606 ◽

2014 ◽

Vol 5 (1) ◽

Cited By ~ 54

Author(s):

Lucy C. Okell ◽

Matthew Cairns ◽

Jamie T. Griffin ◽

Neil M. Ferguson ◽

Joel Tarning ◽

...

Keyword(s):

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Combination Therapies ◽

First Line ◽

Model Based ◽

Effectiveness Analysis ◽

Artemisinin Combination Therapies

Download Full-text

Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada

PharmacoEconomics ◽

10.1007/s40273-021-01022-9 ◽

2021 ◽

Author(s):

Yong-Jin Kim ◽

Mark Oremus ◽

Helen H. Chen ◽

Thomas McFarlane ◽

Danielle Fearon ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Egfr Mutation ◽

Cost Effectiveness Analysis ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis

Download Full-text

P-2 First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis

Annals of Oncology ◽

10.1016/j.annonc.2021.05.057 ◽

2021 ◽

Vol 32 ◽

pp. S97

Author(s):

S. Chan ◽

C. Chiang ◽

S. Lee ◽

H. Choi

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

First Line ◽

Effectiveness Analysis

Download Full-text

Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost‐effectiveness analysis in China and the United states

Liver International ◽

10.1111/liv.14795 ◽

2021 ◽

Vol 41 (5) ◽

pp. 1097-1104

Author(s):

Feng Wen ◽

Hanrui Zheng ◽

Pengfei Zhang ◽

Weiting Liao ◽

Kexun Zhou ◽

...

Keyword(s):

United States ◽

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Systemic Treatment ◽

The United States ◽

Cost Effectiveness Analysis ◽

First Line ◽

Effectiveness Analysis ◽

Unresectable Hepatocellular Carcinoma

Download Full-text

Cost-Effectiveness Analysis Of Panitumumab + Folfox Compared To Cetuximab + Folfiri As First-Line Treatment For Patients With Wild-Type (Wt) Ras (Exons 2, 3, And 4 Of Kras And Nras) Metastatic Colorectal Cancer (Mcrc) In Colombia

Value in Health ◽

10.1016/j.jval.2015.09.1188 ◽

2015 ◽

Vol 18 (7) ◽

pp. A460 ◽

Cited By ~ 2

Author(s):

J Vargas-Valencia ◽

J Garcia Perlaza

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Metastatic Colorectal Cancer ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Model-based cost-effectiveness analysis of interventions aimed at preventing medication error at hospital admission (medicines reconciliation)

Journal of Evaluation in Clinical Practice ◽

10.1111/j.1365-2753.2008.01000.x ◽

2009 ◽

Vol 15 (2) ◽

pp. 299-306 ◽

Cited By ~ 58

Author(s):

Jonathan Karnon ◽

Fiona Campbell ◽

Carolyn Czoski-Murray

Keyword(s):

Cost Effectiveness ◽

Hospital Admission ◽

Medication Error ◽

Cost Effectiveness Analysis ◽

Model Based ◽

Effectiveness Analysis ◽

Medicines Reconciliation

Download Full-text

Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

Journal of Medical Economics ◽

10.1080/13696998.2017.1285780 ◽

2017 ◽

Vol 20 (6) ◽

pp. 574-584 ◽

Cited By ~ 3

Author(s):

Fernando Rivera ◽

Manuel Valladares ◽

Salvador Gea ◽

Noemí López-Martínez

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Metastatic Colorectal Cancer ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost-Effectiveness Analysis Comparing FOLFIRINOX and Nab-Paclitaxel (Abaraxane) Plus Gemcitabine For First-Line Treatment Of Patients with Metastatic Pancreatic Cancer from the US Societal Perspective

Value in Health ◽

10.1016/j.jval.2016.03.1607 ◽

2016 ◽

Vol 19 (3) ◽

pp. A153

Author(s):

W Cheng ◽

JW Hay

Keyword(s):

Pancreatic Cancer ◽

Cost Effectiveness ◽

Societal Perspective ◽

Cost Effectiveness Analysis ◽

Metastatic Pancreatic Cancer ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

The Us ◽

First Line Treatment

Download Full-text

First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial

AIDS ◽

10.1097/qad.0b013e3283428cbe ◽

2011 ◽

Vol 25 (4) ◽

pp. 479-492 ◽

Cited By ~ 21

Author(s):

Andrea L Ciaranello ◽

Shahin Lockman ◽

Kenneth A Freedberg ◽

Michael Hughes ◽

Jennifer Chu ◽

...

Keyword(s):

South Africa ◽

Single Dose ◽

Cost Effectiveness ◽

Antiretroviral Therapy ◽

Cost Effectiveness Analysis ◽

First Line ◽

Effectiveness Analysis ◽

Single Dose Nevirapine

Download Full-text

Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder

International Urogynecology Journal ◽

10.1007/s00192-018-3662-y ◽

2018 ◽

Vol 29 (8) ◽

pp. 1221-1221

Author(s):

Abdelmageed Abdelrahman

Keyword(s):

Cost Effectiveness ◽

Overactive Bladder ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

Onabotulinumtoxin A ◽

First Line Treatment

Download Full-text

Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong

Cost Effectiveness and Resource Allocation ◽

10.1186/s12962-020-0200-9 ◽

2020 ◽

Vol 18 (1) ◽

Cited By ~ 1

Author(s):

Herbert H. Loong ◽

Carlos K. H. Wong ◽

Linda K. S. Leung ◽

S. C. Tan ◽

Jason Jen ◽

...

Keyword(s):

Hong Kong ◽

Cost Effectiveness ◽

Standard Of Care ◽

Cost Effectiveness Analysis ◽

Advanced Melanoma ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text